Challenges in Management of Pediatric HIV/ AIDS: Thailand Perspective
Keywords:
No KeywordAbstract
No Abstract
References
1. UNAIDS. Global report 2010. Available from: http://www.unaids.org/
globalreport/Global_report.htm. Access February 7, 2011.
2. MOPH. Available from: http://www.boe.moph.go.th/files/report/20110201_
64960619.pdf. Access February 7, 2011.
3. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna
MT. Revised surveillance case definitions for HIV infection among adults,
adolescents, and children aged <18 months and for HIV infection and
AIDS among children aged 18 months to <13 years--United States, 2008.
MMWR Recomm Rep. 2008 Dec 5;57(RR-10):1-12.
4. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al.
Early antiretroviral therapy and mortality among HIV-infected infants.
N Engl J Med. 2008 Nov 20;359(21):2233-44.
5. CDC. 1994 Revised Classification System for Human Immunodeficiency
Virus Infection in Children Less Than 13 Years of Age. Official Authorized
Addenda: Human Immunodeficiency Virus Infection Codes and
Official Guidelines for Coding and Reporting ICD-9-CM. MMWR 1994;
43(RR-12):1-19.
6. WHO case definitions of HIV for surveillance and revised clinical staging
and immunological classification of HIV-related disease in adults and
children. Available from: http://www.who.int/hiv/pub/guidelines/hivstaging/
en/index.html. Access February 7, 2011.
7. Puthanakita T, Tangsathapornpongb A, Ananworanichc J, et al. Thai
national guidelines for the use of antiretroviral therapy in pediatric HIV
infection in 2010. Asian Biomed. 2010;4(4):505-513.
8. Chalermchockcharoenkit A, Culnane M, Chotpitayasunondh T, Vanprapa
N, Leelawiwat W, Mock PA, et al. Antiretroviral resistance patterns and
HIV-1 subtype in mother-infant pairs after the administration of combination
short-course zidovudine plus single-dose nevirapine for the prevention
of mother-to-child transmission of HIV. Clin Infect Dis. 2009 Jul 15;49
(2):299-305.
9. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T,
et al. Antiretroviral treatment for children with peripartum nevirapine
exposure. N Engl J Med. 2010 Oct 14;363(16):1510-20.
10. Chokephaibulkit K, Plipat N, Cressey TR, Frederix K, Phongsamart W,
Capparelli E, et al. Pharmacokinetics of nevirapine in HIV-infected
children receiving an adult fixed-dose combination of stavudine, lamivudine
and nevirapine. AIDS. 2005 Sep 23;19(14):1495-9.
11. Puthanakit T, Aurpibul L, Oberdorfer P, Akarathum N, Kanjanavanit S,
Wannarit P, et al. Sustained immunologic and virologic efficacy after
four years of highly active antiretroviral therapy in human immunodeficiency
virus infected children in Thailand. Pediatr Infect Dis J. 2007
Oct;26(10):953-6.
12. De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G. Periconceptional
exposure to efavirenz and neural tube defects. Arch Intern
Med. 2002 Feb 11;162(3):355.
13. Fundarò C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele
in a child with intrauterine exposure to efavirenz. AIDS. 2002
Jan 25;16(2):299-300.
14. Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph
S. Standard-dose efavirenz vs. standard-dose nevirapine in
antiretroviral regimens among HIV-1 and tuberculosis co-infected patients
who received rifampicin. HIV Med. 2008 May;9(5):294-9.
15. Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich
A, Prasithsirikul W, et al. Plasma nevirapine levels and 24-week
efficacy in HIV-infected patients receiving nevirapine-based highly active
antiretroviral therapy with or without rifampicin. Clin Infect Dis.
2006 Jul 15;43(2):253-5.
16. Bunupuradah T, Suntarattiwong P, Li A, Sirivichayakul S, Pancharoen C,
Boonrak P, et al. Antiretroviral treatment outcome following genotyping
in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
Int J Infect Dis. 2010 Apr;14(4):e311-6.
17. Lolekha R, Sirivichayakul S, Siangphoe U, Pancharoen C, Kaewchana S,
Apateerapong W, et al. Resistance to dual nucleoside reverse-transcriptase
inhibitors in children infected with HIV clade A/E. Clin Infect Dis. 2005
Jan 15;40(2):309-12.
18. Plipat N, Cressey TR, Vanprapar N, Chokephaibulkit K. Efficacy and
plasma concentrations of indinavir when boosted with ritonavir in human
immunodeficiency virus-infected Thai children. Pediatr Infect Dis J. 2007
Jan;26(1):86-8.
19. Ananworanich J, Kosalaraksa P, Hill A, Siangphoe U, Bergshoeff A,
Pancharoen C, et al. Pharmacokinetics and 24-week efficacy/safety of dual
boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.
Pediatr Infect Dis J. 2005 Oct;24(10):874-9.
20. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick
M et al. Selection and fading of resistance mutations in women
and infants receiving nevirapine to prevent HIV-1 vertical transmission
(HIVNET 012). AIDS. 2001 Oct 19;15(15):1951-7.
21. Troyer RM, Lalonde MS, Fraundorf E, Demers KR, Kyeyune F, Mugyenyi
P, et al. A radiolabeled oligonucleotide ligation assay demonstrates
the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies
of NVP-treated and untreated mother-infant pairs from Uganda.
AIDS Res Hum Retroviruses. 2008 Feb;24(2):235-50.
22. Hurt CB, McCoy SI, Kuruc J, Nelson JA, Kerkau M, Fiscus S, et al.
Transmitted antiretroviral drug resistance among acute and recent HIV
infections in North Carolina from 1998 to 2007. Antivir Ther. 2009;14(5):
673-8.
23. Chakraborty R, Smith CJ, Dunn D, Green H, Duong T, Doerholt K, et al.
HIV-1 drug resistance in HIV-1-infected children in the United Kingdom
from 1998 to 2004. Pediatr Infect Dis J. 2008 May;27(5):457-9.
24. Gupta RK, Ford D, Mulenga V, Walker AS, Kabamba D, Kalumbi M,
et al. Drug resistance in human immunodeficiency virus type-1 infected
Zambian children using adult fixed dose combination stavudine, lamivudine,
and nevirapine. Pediatr Infect Dis J. 2010 Aug;29(8):e57-62.
25. Ayouba A, Lien TT, Nouhin J, Vergne L, Aghokeng AF, Ngo-Giang-
Huong N et al. Low prevalence of HIV type 1 drug resistance mutations
in untreated, recently infected patients from Burkina Faso, Cote d’Ivoire,
Senegal, Thailand, and Vietnam: the ANRS 12134 study. AIDS Res Hum
Retroviruses. 2009 Nov;25(11):1193-6.
26. Puthanakit T, Jourdain G, Hongsiriwon S, Suntarattiwong P, Chokephaibulkit
K, Sirisanthana V, et al. HIV-1 drug resistance mutations in children
after failure of first-line nonnucleoside reverse transcriptase inhibitorbased
antiretroviral therapy. HIV Med. 2010 Oct 1;11(9):565-72.
27. Scaling up antiretroviral therapy in resource limited settings: guidelines
for a public health approach. Geneva: World Health Organization, June
2002. Available from: http://www. who.int/hiv/topics/arv/ISBN9241545674.
pdf. Access February 7, 2011.
28. Carter RJ, Wiener J, Abrams EJ, Farley J, Nesheim S, Palumbo P, et al.
Dyslipidemia among perinatally HIV-infected children enrolled in the
PACTS-HOPE cohort, 1999-2004: a longitudinal analysis. J Acquir Immune
Defic Syndr. 2006 Apr 1;41(4):453-60.
29. Scherpbier HJ, Bekker V, van Leth F, Jurriaans S, Lange JM, Kuijpers
TW. Long-term experience with combination antiretroviral therapy that
contains nelfinavir for up to 7 years in a pediatric cohort. Pediatrics.
2006 Mar;117(3):e528-36.
30. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat
redistribution and hyperlipidaemia in HIV-infected children in Europe.
AIDS. 2004 Jul 2;18(10):1443-51.
31. Sánchez Torres AM, Munoz Muniz R, Madero R, Borque C, García-
Miguel MJ, De José Gómez MI. Prevalence of fat redistribution and
metabolic disorders in human immunodeficiency virus-infected children.
Eur J Pediatr. 2005 May;164(5):271-6.
32. Aurpibul L, Puthanakit T, Lee B, Mangklabruks A, Sirisanthana T, Sirisanthana
V. Lipodystrophy and metabolic changes in HIV-infected children
on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Antivir Ther. 2007;12(8):1247-54.
33. Taylor P, Worrell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV,
et al. Natural history of lipid abnormalities and fat redistribution among
human immunodeficiency virus-infected children receiving long-term,
protease inhibitor-containing, highly active antiretroviral therapy regimens.
Pediatrics. 2004 Aug;114(2):e235-42.
34. Ene L, Goetghebuer T, Hainaut M, Peltier A, Toppet V, Levy J. Prevalence
of lipodystrophy in HIV-infected children: a cross-sectional study.
Eur J Pediatr. 2007 Jan;166(1):13-21.
35. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected
Children. Guidelines for the Use of Antiretroviral Agents in Pediatric
HIV Infection. August 16, 2010; pp 1-219. [updated 2010 August 16;
cited 2011 Jan 7]. Available from: http://aidsinfo.nih.gov/ContentFiles/
PediatricGuidelines.pdf. Access February 7, 2011.
36. Funk E, Brissett AE, Friedman CD, Bressler FJ. HIV-associated facial
lipoatrophy: establishment of a validated grading scale. Laryngoscope.
2007 Aug;117(8):1349-53.
37. Drechsler H, Powderly WG. Switching effective antiretroviral therapy:
a review. Clin Infect Dis. 2002 Nov 15;35(10):1219-30.
38. Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, et al. Abacavir
substitution for nucleoside analogs in patients with HIV lipoatrophy: a
randomized trial. JAMA. 2002 Jul 10;288(2):207-15.
39. McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P,
Lonergan JT, et al. Improvement in lipoatrophy associated with highly
active antiretroviral therapy in human immunodeficiency virus-infected
patients switched from stavudine to abacavir or zidovudine: the results
of the TARHEEL study. Clin Infect Dis. 2004 Jan 15;38(2):263-70.
40. Wohl DA, McComsey G, Tebas P, Brown TT, Glesby MJ, Reeds D, et al.
Current concepts in the diagnosis and management of metabolic complications
of HIV infection and its therapy. Clin Infect Dis. 2006 Sep 1;43(5):
645-53.
41. WHO. Antiretroviral therapy for HIV infection in infants and children:
Towards universal access Recommendations for a public health approach:
2010 revision. Available from: http://www.who.int/hiv/pub/paediatric/
infants2010/en/index.html. Access February 7, 2011.
42. Tassiopoulos K, Williams PL, Seage GR 3rd, Crain M, Oleske J, Farley J.
Association of hypercholesterolemia incidence with antiretroviral treatment,
including protease inhibitors, among perinatally HIV-infected children.
J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):607-14.
43. Aldrovandi GM, Lindsey JC, Jacobson DL, Zadzilka A, Sheeran E, Moye
J, et al. Morphologic and metabolic abnormalities in vertically HIVinfected
children and youth. AIDS. 2009 Mar 27;23(6):661-72.
44. Kim RJ, Rutstein RM. Impact of antiretroviral therapy on growth, body
composition and metabolism in pediatric HIV patients. Paediatr Drugs.
2010 Jun;12(3):187-99.
45. Farley J, Gona P, Crain M, Cervia J, Oleske J, Seage G, et al. Prevalence
of elevated cholesterol and associated risk factors among perinatally HIVinfected
children (4-19 years old) in Pediatric AIDS Clinical Trials Group
219C. J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):480-7.
46. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood
KC, et al. Protease inhibitors and cardiovascular outcomes in patients
with HIV-1. Lancet. 2002 Nov 30;360(9347):1747-8.
47. Holmberg SD, Moorman AC, Greenberg AE. Trends in rates of myocardial
infarction among patients with HIV. N Engl J Med. 2004 Feb 12;350
(7):730-2
48. Friis-Moller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM,
Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial
infarction. N Engl J Med. 2003 Nov 20;349(21):1993-2003.
49. Fisac C, Fumero E, Crespo M, Roson B, Ferrer E, Virgili N, et al. Metabolic
benefits 24 months after replacing a protease inhibitor with abacavir,
efavirenz or nevirapine. AIDS. 2005 Jun 10;19(9):917-25.
50. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, Stoll M, Esser S, Voigt
E, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-
experienced patients with severe hyperlipidemia. J Acquir Immune
Defic Syndr. 2005 Jun 1;39(2):174-80.
51. Domingo P, Labarga P, Palacios R, Guerro MF, Terròn JA, Elías MJ,
et al. Improvement of dyslipidemia in patients switching from stavudine
to tenofovir: preliminary results. AIDS. 2004 Jul 2;18(10):1475-8.
52. Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW.
Lipodystrophy syndrome in human immunodeficiency virus-infected children.
Pediatr Infect Dis J. 2002 May;21(5):405-10.
53. Vigano A, Brambilla P, Pattarino G, Stucchi S, Fasan S, Raimondi C, et al.
Long-term evaluation of glucose homeostasis in a cohort of HAARTtreated
HIV-infected children: a longitudinal, observational cohort study.
Clin Drug Investig. 2009;29(2):101-9.
54. Bitnun A, Sochett E, Dick PT, To T, Jefferies C, Babyn P, et al. Insulin
sensitivity and beta-cell function in protease inhibitor-treated and -naive
human immunodeficiency virus-infected children. J Clin Endocrinol Metab.
2005 Jan;90(1):168-74.
55. Lee B, Aurpibul L, Sirisanthana V, Mangklabruks A, Sirisanthana T,
Puthanakit T. Low prevalence of insulin resistance among HIV-infected
children receiving nonnucleoside reverse transcriptase inhibitor-based
highly active antiretroviral therapy in Thailand. HIV Med. 2009 Feb;10
(2):72-8.
56. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum
SL, et al. Accelerated bone mineral loss in HIV-infected patients receiving
potent antiretroviral therapy. AIDS. 2000 Mar 10;14(4):F63-7.
57. Fairfield WP, Finkelstein JS, Klibanski A, Grinspoon SK. Osteopenia in
eugonadal men with acquired immune deficiency syndrome wasting syndrome.
J Clin Endocrinol Metab. 2001 May;86(5):2020-6.
58. Knobel H, Guelar A, Vallecillo G, Nogués X, Díez A. Osteopenia in
HIV-infected patients: is it the disease or is it the treatment? AIDS. 2001
Apr 13;15(6):807-8.
59. Fessel WJ, Hurley LB. Is HIV sequestered in bone? Possible implications
of virological and immunological findings in some HIV-infected patients
with bone disease. Aids. 2003;17:255-7.
60. Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E,
et al. Tenofovir disoproxil fumarate and an optimized background regimen
of antiretroviral agents as salvage therapy: impact on bone mineral density
in HIV-infected children. Pediatrics. 2006 Sep;118(3):e711-8.
61. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone
mineral density with off-label use of tenofovir in children and adolescents
infected with human immunodeficiency virus. J Pediatr. 2008 Apr;152(4):
582-4.
62. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller
MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination
therapy in antiretroviral-naive patients: a 3-year randomized trial.
JAMA. 2004 Jul 14;292(2):191-201.
63. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, et al.
Tenofovir-associated renal and bone toxicity. HIV Med. 2009 Sep;10(8):
482-7.
64. Viganò A, Zuccotti GV, Martelli L, Giacomet V, Cafarelli L, Borgonovo S,
et al. Renal safety of tenofovir in HIV-infected children: a prospective,
96-week longitudinal study. Clin Drug Investig. 2007;27(8):573-81.
65. Rho M, Perazella MA. Nephrotoxicity associated with antiretroviral therapy
in HIV-infected patients. Curr Drug Saf. 2007 May;2(2):147-54.
66. Jao J, Wyatt CM. Antiretroviral medications: adverse effects on the kidney.
Adv Chronic Kidney Dis. 2010 Jan;17(1):72-82.
67. Disclosure of illness status to children and adolescents with HIV infection.
American Academy of Pediatrics Committee on Pediatrics AIDS. Pediatrics.
1999 Jan;103(1):164-6.
68. Lipson M. Disclosure of diagnosis to children with human immunodeficiency
virus or acquired immunodeficiency syndrome. J Dev Behav
Pediatr. 1994;15:S61-5.
69. Wiener LS, Battles HB, Heilman N, Sigelman CK, Pizzo PA. Factors
associated with disclosure of diagnosis to children with HIV/AIDS. Pediatr
AIDS HIV Infect. 1996 Oct;7(5):310-24.
70. Blasini I, Chantry C, Cruz C, Ortiz L, Salabarría I, Scalley N, et al.
Disclosure model for pediatric patients living with HIV in Puerto Rico:
design, implementation, and evaluation. J Dev Behav Pediatr. 2004 Jun;25
(3):181-9.
71. Boon-Yasidhi V, Kottapat U, Durier Y, Plipat N, Phongsamart W, Chokephaibulkit
K, et al. Diagnosis disclosure in HIV-infected Thai children.
J Med Assoc Thai. 2005 Nov;88 Suppl 8:S100-5.
72. Funck-Brentano I, Costagliola D, Seibel N, Straub E, Tardieu M, Blanche S.
Patterns of disclosure and perceptions of the human immunodeficiency
virus in infected elementary school-age children. Arch Pediatr Adolesc
Med. 1997 Oct;151(10):978-85.
73. Kouyoumdjian FG, Meyers T, Mtshizana S. Barriers to disclosure to
children with HIV. J Trop Pediatr. 2005;51:285-7.
74. Punpanich W, Boon-Yasidhi V, Chokephaibulkit K, Prasitsuebsai W, Chantbuddhiwet
U, Leowsrisook P, et al. Health-related Quality of Life of
Thai children with HIV infection: a comparison of the Thai Quality of Life
in Children (ThQLC) with the Pediatric Quality of Life InventoryTM
version 4.0 (PedsQLTM 4.0) Generic Core Scales. Qual Life Res. 2010
Dec;19(10):1509-16.
75. Williams PL, Storm D, Montepiedra G, Nichols S, Kammerer B, Sirois
PA, et al. Predictors of adherence to antiretroviral medications in children
and adolescents with HIV infection. Pediatrics. 2006 Dec;118(6):e1745-57.
76. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg
L, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes
in adolescents compared with adults in southern Africa. J Acquir
Immune Defic Syndr. 2009 May 1;51(1):65-71.
77. Rongkavilit C, Naar-King S, Chuenyam T, Wang B, Wright K, Phanuphak
P. Health risk behaviors among HIV-infected youth in Bangkok, Thailand.
J Adolesc Health. 2007 Apr;40(4):358.e1-8.
78. Brogly SB, Watts DH, Ylitalo N, Franco EL, Seage GR 3rd, Oleske J,
et al. Reproductive health of adolescent girls perinatally infected with
HIV. Am J Public Health. 2007 Jun;97(6):1047-52.
globalreport/Global_report.htm. Access February 7, 2011.
2. MOPH. Available from: http://www.boe.moph.go.th/files/report/20110201_
64960619.pdf. Access February 7, 2011.
3. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna
MT. Revised surveillance case definitions for HIV infection among adults,
adolescents, and children aged <18 months and for HIV infection and
AIDS among children aged 18 months to <13 years--United States, 2008.
MMWR Recomm Rep. 2008 Dec 5;57(RR-10):1-12.
4. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al.
Early antiretroviral therapy and mortality among HIV-infected infants.
N Engl J Med. 2008 Nov 20;359(21):2233-44.
5. CDC. 1994 Revised Classification System for Human Immunodeficiency
Virus Infection in Children Less Than 13 Years of Age. Official Authorized
Addenda: Human Immunodeficiency Virus Infection Codes and
Official Guidelines for Coding and Reporting ICD-9-CM. MMWR 1994;
43(RR-12):1-19.
6. WHO case definitions of HIV for surveillance and revised clinical staging
and immunological classification of HIV-related disease in adults and
children. Available from: http://www.who.int/hiv/pub/guidelines/hivstaging/
en/index.html. Access February 7, 2011.
7. Puthanakita T, Tangsathapornpongb A, Ananworanichc J, et al. Thai
national guidelines for the use of antiretroviral therapy in pediatric HIV
infection in 2010. Asian Biomed. 2010;4(4):505-513.
8. Chalermchockcharoenkit A, Culnane M, Chotpitayasunondh T, Vanprapa
N, Leelawiwat W, Mock PA, et al. Antiretroviral resistance patterns and
HIV-1 subtype in mother-infant pairs after the administration of combination
short-course zidovudine plus single-dose nevirapine for the prevention
of mother-to-child transmission of HIV. Clin Infect Dis. 2009 Jul 15;49
(2):299-305.
9. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T,
et al. Antiretroviral treatment for children with peripartum nevirapine
exposure. N Engl J Med. 2010 Oct 14;363(16):1510-20.
10. Chokephaibulkit K, Plipat N, Cressey TR, Frederix K, Phongsamart W,
Capparelli E, et al. Pharmacokinetics of nevirapine in HIV-infected
children receiving an adult fixed-dose combination of stavudine, lamivudine
and nevirapine. AIDS. 2005 Sep 23;19(14):1495-9.
11. Puthanakit T, Aurpibul L, Oberdorfer P, Akarathum N, Kanjanavanit S,
Wannarit P, et al. Sustained immunologic and virologic efficacy after
four years of highly active antiretroviral therapy in human immunodeficiency
virus infected children in Thailand. Pediatr Infect Dis J. 2007
Oct;26(10):953-6.
12. De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G. Periconceptional
exposure to efavirenz and neural tube defects. Arch Intern
Med. 2002 Feb 11;162(3):355.
13. Fundarò C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele
in a child with intrauterine exposure to efavirenz. AIDS. 2002
Jan 25;16(2):299-300.
14. Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph
S. Standard-dose efavirenz vs. standard-dose nevirapine in
antiretroviral regimens among HIV-1 and tuberculosis co-infected patients
who received rifampicin. HIV Med. 2008 May;9(5):294-9.
15. Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich
A, Prasithsirikul W, et al. Plasma nevirapine levels and 24-week
efficacy in HIV-infected patients receiving nevirapine-based highly active
antiretroviral therapy with or without rifampicin. Clin Infect Dis.
2006 Jul 15;43(2):253-5.
16. Bunupuradah T, Suntarattiwong P, Li A, Sirivichayakul S, Pancharoen C,
Boonrak P, et al. Antiretroviral treatment outcome following genotyping
in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
Int J Infect Dis. 2010 Apr;14(4):e311-6.
17. Lolekha R, Sirivichayakul S, Siangphoe U, Pancharoen C, Kaewchana S,
Apateerapong W, et al. Resistance to dual nucleoside reverse-transcriptase
inhibitors in children infected with HIV clade A/E. Clin Infect Dis. 2005
Jan 15;40(2):309-12.
18. Plipat N, Cressey TR, Vanprapar N, Chokephaibulkit K. Efficacy and
plasma concentrations of indinavir when boosted with ritonavir in human
immunodeficiency virus-infected Thai children. Pediatr Infect Dis J. 2007
Jan;26(1):86-8.
19. Ananworanich J, Kosalaraksa P, Hill A, Siangphoe U, Bergshoeff A,
Pancharoen C, et al. Pharmacokinetics and 24-week efficacy/safety of dual
boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.
Pediatr Infect Dis J. 2005 Oct;24(10):874-9.
20. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick
M et al. Selection and fading of resistance mutations in women
and infants receiving nevirapine to prevent HIV-1 vertical transmission
(HIVNET 012). AIDS. 2001 Oct 19;15(15):1951-7.
21. Troyer RM, Lalonde MS, Fraundorf E, Demers KR, Kyeyune F, Mugyenyi
P, et al. A radiolabeled oligonucleotide ligation assay demonstrates
the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies
of NVP-treated and untreated mother-infant pairs from Uganda.
AIDS Res Hum Retroviruses. 2008 Feb;24(2):235-50.
22. Hurt CB, McCoy SI, Kuruc J, Nelson JA, Kerkau M, Fiscus S, et al.
Transmitted antiretroviral drug resistance among acute and recent HIV
infections in North Carolina from 1998 to 2007. Antivir Ther. 2009;14(5):
673-8.
23. Chakraborty R, Smith CJ, Dunn D, Green H, Duong T, Doerholt K, et al.
HIV-1 drug resistance in HIV-1-infected children in the United Kingdom
from 1998 to 2004. Pediatr Infect Dis J. 2008 May;27(5):457-9.
24. Gupta RK, Ford D, Mulenga V, Walker AS, Kabamba D, Kalumbi M,
et al. Drug resistance in human immunodeficiency virus type-1 infected
Zambian children using adult fixed dose combination stavudine, lamivudine,
and nevirapine. Pediatr Infect Dis J. 2010 Aug;29(8):e57-62.
25. Ayouba A, Lien TT, Nouhin J, Vergne L, Aghokeng AF, Ngo-Giang-
Huong N et al. Low prevalence of HIV type 1 drug resistance mutations
in untreated, recently infected patients from Burkina Faso, Cote d’Ivoire,
Senegal, Thailand, and Vietnam: the ANRS 12134 study. AIDS Res Hum
Retroviruses. 2009 Nov;25(11):1193-6.
26. Puthanakit T, Jourdain G, Hongsiriwon S, Suntarattiwong P, Chokephaibulkit
K, Sirisanthana V, et al. HIV-1 drug resistance mutations in children
after failure of first-line nonnucleoside reverse transcriptase inhibitorbased
antiretroviral therapy. HIV Med. 2010 Oct 1;11(9):565-72.
27. Scaling up antiretroviral therapy in resource limited settings: guidelines
for a public health approach. Geneva: World Health Organization, June
2002. Available from: http://www. who.int/hiv/topics/arv/ISBN9241545674.
pdf. Access February 7, 2011.
28. Carter RJ, Wiener J, Abrams EJ, Farley J, Nesheim S, Palumbo P, et al.
Dyslipidemia among perinatally HIV-infected children enrolled in the
PACTS-HOPE cohort, 1999-2004: a longitudinal analysis. J Acquir Immune
Defic Syndr. 2006 Apr 1;41(4):453-60.
29. Scherpbier HJ, Bekker V, van Leth F, Jurriaans S, Lange JM, Kuijpers
TW. Long-term experience with combination antiretroviral therapy that
contains nelfinavir for up to 7 years in a pediatric cohort. Pediatrics.
2006 Mar;117(3):e528-36.
30. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat
redistribution and hyperlipidaemia in HIV-infected children in Europe.
AIDS. 2004 Jul 2;18(10):1443-51.
31. Sánchez Torres AM, Munoz Muniz R, Madero R, Borque C, García-
Miguel MJ, De José Gómez MI. Prevalence of fat redistribution and
metabolic disorders in human immunodeficiency virus-infected children.
Eur J Pediatr. 2005 May;164(5):271-6.
32. Aurpibul L, Puthanakit T, Lee B, Mangklabruks A, Sirisanthana T, Sirisanthana
V. Lipodystrophy and metabolic changes in HIV-infected children
on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Antivir Ther. 2007;12(8):1247-54.
33. Taylor P, Worrell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV,
et al. Natural history of lipid abnormalities and fat redistribution among
human immunodeficiency virus-infected children receiving long-term,
protease inhibitor-containing, highly active antiretroviral therapy regimens.
Pediatrics. 2004 Aug;114(2):e235-42.
34. Ene L, Goetghebuer T, Hainaut M, Peltier A, Toppet V, Levy J. Prevalence
of lipodystrophy in HIV-infected children: a cross-sectional study.
Eur J Pediatr. 2007 Jan;166(1):13-21.
35. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected
Children. Guidelines for the Use of Antiretroviral Agents in Pediatric
HIV Infection. August 16, 2010; pp 1-219. [updated 2010 August 16;
cited 2011 Jan 7]. Available from: http://aidsinfo.nih.gov/ContentFiles/
PediatricGuidelines.pdf. Access February 7, 2011.
36. Funk E, Brissett AE, Friedman CD, Bressler FJ. HIV-associated facial
lipoatrophy: establishment of a validated grading scale. Laryngoscope.
2007 Aug;117(8):1349-53.
37. Drechsler H, Powderly WG. Switching effective antiretroviral therapy:
a review. Clin Infect Dis. 2002 Nov 15;35(10):1219-30.
38. Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, et al. Abacavir
substitution for nucleoside analogs in patients with HIV lipoatrophy: a
randomized trial. JAMA. 2002 Jul 10;288(2):207-15.
39. McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P,
Lonergan JT, et al. Improvement in lipoatrophy associated with highly
active antiretroviral therapy in human immunodeficiency virus-infected
patients switched from stavudine to abacavir or zidovudine: the results
of the TARHEEL study. Clin Infect Dis. 2004 Jan 15;38(2):263-70.
40. Wohl DA, McComsey G, Tebas P, Brown TT, Glesby MJ, Reeds D, et al.
Current concepts in the diagnosis and management of metabolic complications
of HIV infection and its therapy. Clin Infect Dis. 2006 Sep 1;43(5):
645-53.
41. WHO. Antiretroviral therapy for HIV infection in infants and children:
Towards universal access Recommendations for a public health approach:
2010 revision. Available from: http://www.who.int/hiv/pub/paediatric/
infants2010/en/index.html. Access February 7, 2011.
42. Tassiopoulos K, Williams PL, Seage GR 3rd, Crain M, Oleske J, Farley J.
Association of hypercholesterolemia incidence with antiretroviral treatment,
including protease inhibitors, among perinatally HIV-infected children.
J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):607-14.
43. Aldrovandi GM, Lindsey JC, Jacobson DL, Zadzilka A, Sheeran E, Moye
J, et al. Morphologic and metabolic abnormalities in vertically HIVinfected
children and youth. AIDS. 2009 Mar 27;23(6):661-72.
44. Kim RJ, Rutstein RM. Impact of antiretroviral therapy on growth, body
composition and metabolism in pediatric HIV patients. Paediatr Drugs.
2010 Jun;12(3):187-99.
45. Farley J, Gona P, Crain M, Cervia J, Oleske J, Seage G, et al. Prevalence
of elevated cholesterol and associated risk factors among perinatally HIVinfected
children (4-19 years old) in Pediatric AIDS Clinical Trials Group
219C. J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):480-7.
46. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood
KC, et al. Protease inhibitors and cardiovascular outcomes in patients
with HIV-1. Lancet. 2002 Nov 30;360(9347):1747-8.
47. Holmberg SD, Moorman AC, Greenberg AE. Trends in rates of myocardial
infarction among patients with HIV. N Engl J Med. 2004 Feb 12;350
(7):730-2
48. Friis-Moller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM,
Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial
infarction. N Engl J Med. 2003 Nov 20;349(21):1993-2003.
49. Fisac C, Fumero E, Crespo M, Roson B, Ferrer E, Virgili N, et al. Metabolic
benefits 24 months after replacing a protease inhibitor with abacavir,
efavirenz or nevirapine. AIDS. 2005 Jun 10;19(9):917-25.
50. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, Stoll M, Esser S, Voigt
E, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-
experienced patients with severe hyperlipidemia. J Acquir Immune
Defic Syndr. 2005 Jun 1;39(2):174-80.
51. Domingo P, Labarga P, Palacios R, Guerro MF, Terròn JA, Elías MJ,
et al. Improvement of dyslipidemia in patients switching from stavudine
to tenofovir: preliminary results. AIDS. 2004 Jul 2;18(10):1475-8.
52. Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW.
Lipodystrophy syndrome in human immunodeficiency virus-infected children.
Pediatr Infect Dis J. 2002 May;21(5):405-10.
53. Vigano A, Brambilla P, Pattarino G, Stucchi S, Fasan S, Raimondi C, et al.
Long-term evaluation of glucose homeostasis in a cohort of HAARTtreated
HIV-infected children: a longitudinal, observational cohort study.
Clin Drug Investig. 2009;29(2):101-9.
54. Bitnun A, Sochett E, Dick PT, To T, Jefferies C, Babyn P, et al. Insulin
sensitivity and beta-cell function in protease inhibitor-treated and -naive
human immunodeficiency virus-infected children. J Clin Endocrinol Metab.
2005 Jan;90(1):168-74.
55. Lee B, Aurpibul L, Sirisanthana V, Mangklabruks A, Sirisanthana T,
Puthanakit T. Low prevalence of insulin resistance among HIV-infected
children receiving nonnucleoside reverse transcriptase inhibitor-based
highly active antiretroviral therapy in Thailand. HIV Med. 2009 Feb;10
(2):72-8.
56. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum
SL, et al. Accelerated bone mineral loss in HIV-infected patients receiving
potent antiretroviral therapy. AIDS. 2000 Mar 10;14(4):F63-7.
57. Fairfield WP, Finkelstein JS, Klibanski A, Grinspoon SK. Osteopenia in
eugonadal men with acquired immune deficiency syndrome wasting syndrome.
J Clin Endocrinol Metab. 2001 May;86(5):2020-6.
58. Knobel H, Guelar A, Vallecillo G, Nogués X, Díez A. Osteopenia in
HIV-infected patients: is it the disease or is it the treatment? AIDS. 2001
Apr 13;15(6):807-8.
59. Fessel WJ, Hurley LB. Is HIV sequestered in bone? Possible implications
of virological and immunological findings in some HIV-infected patients
with bone disease. Aids. 2003;17:255-7.
60. Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E,
et al. Tenofovir disoproxil fumarate and an optimized background regimen
of antiretroviral agents as salvage therapy: impact on bone mineral density
in HIV-infected children. Pediatrics. 2006 Sep;118(3):e711-8.
61. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone
mineral density with off-label use of tenofovir in children and adolescents
infected with human immunodeficiency virus. J Pediatr. 2008 Apr;152(4):
582-4.
62. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller
MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination
therapy in antiretroviral-naive patients: a 3-year randomized trial.
JAMA. 2004 Jul 14;292(2):191-201.
63. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, et al.
Tenofovir-associated renal and bone toxicity. HIV Med. 2009 Sep;10(8):
482-7.
64. Viganò A, Zuccotti GV, Martelli L, Giacomet V, Cafarelli L, Borgonovo S,
et al. Renal safety of tenofovir in HIV-infected children: a prospective,
96-week longitudinal study. Clin Drug Investig. 2007;27(8):573-81.
65. Rho M, Perazella MA. Nephrotoxicity associated with antiretroviral therapy
in HIV-infected patients. Curr Drug Saf. 2007 May;2(2):147-54.
66. Jao J, Wyatt CM. Antiretroviral medications: adverse effects on the kidney.
Adv Chronic Kidney Dis. 2010 Jan;17(1):72-82.
67. Disclosure of illness status to children and adolescents with HIV infection.
American Academy of Pediatrics Committee on Pediatrics AIDS. Pediatrics.
1999 Jan;103(1):164-6.
68. Lipson M. Disclosure of diagnosis to children with human immunodeficiency
virus or acquired immunodeficiency syndrome. J Dev Behav
Pediatr. 1994;15:S61-5.
69. Wiener LS, Battles HB, Heilman N, Sigelman CK, Pizzo PA. Factors
associated with disclosure of diagnosis to children with HIV/AIDS. Pediatr
AIDS HIV Infect. 1996 Oct;7(5):310-24.
70. Blasini I, Chantry C, Cruz C, Ortiz L, Salabarría I, Scalley N, et al.
Disclosure model for pediatric patients living with HIV in Puerto Rico:
design, implementation, and evaluation. J Dev Behav Pediatr. 2004 Jun;25
(3):181-9.
71. Boon-Yasidhi V, Kottapat U, Durier Y, Plipat N, Phongsamart W, Chokephaibulkit
K, et al. Diagnosis disclosure in HIV-infected Thai children.
J Med Assoc Thai. 2005 Nov;88 Suppl 8:S100-5.
72. Funck-Brentano I, Costagliola D, Seibel N, Straub E, Tardieu M, Blanche S.
Patterns of disclosure and perceptions of the human immunodeficiency
virus in infected elementary school-age children. Arch Pediatr Adolesc
Med. 1997 Oct;151(10):978-85.
73. Kouyoumdjian FG, Meyers T, Mtshizana S. Barriers to disclosure to
children with HIV. J Trop Pediatr. 2005;51:285-7.
74. Punpanich W, Boon-Yasidhi V, Chokephaibulkit K, Prasitsuebsai W, Chantbuddhiwet
U, Leowsrisook P, et al. Health-related Quality of Life of
Thai children with HIV infection: a comparison of the Thai Quality of Life
in Children (ThQLC) with the Pediatric Quality of Life InventoryTM
version 4.0 (PedsQLTM 4.0) Generic Core Scales. Qual Life Res. 2010
Dec;19(10):1509-16.
75. Williams PL, Storm D, Montepiedra G, Nichols S, Kammerer B, Sirois
PA, et al. Predictors of adherence to antiretroviral medications in children
and adolescents with HIV infection. Pediatrics. 2006 Dec;118(6):e1745-57.
76. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg
L, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes
in adolescents compared with adults in southern Africa. J Acquir
Immune Defic Syndr. 2009 May 1;51(1):65-71.
77. Rongkavilit C, Naar-King S, Chuenyam T, Wang B, Wright K, Phanuphak
P. Health risk behaviors among HIV-infected youth in Bangkok, Thailand.
J Adolesc Health. 2007 Apr;40(4):358.e1-8.
78. Brogly SB, Watts DH, Ylitalo N, Franco EL, Seage GR 3rd, Oleske J,
et al. Reproductive health of adolescent girls perinatally infected with
HIV. Am J Public Health. 2007 Jun;97(6):1047-52.
Downloads
Published
03-04-2020
How to Cite
Phongsamart, W. ., Wittawatmongkol, O. ., Vanprapar, N. ., & Chokephaibulkit, K. . (2020). Challenges in Management of Pediatric HIV/ AIDS: Thailand Perspective. Siriraj Medical Journal, 63(1), 25–31. Retrieved from https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/240901
Issue
Section
Special Issue
License
Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:
- Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
